Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的人是患丙型肝炎的高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙肝感染者中，重叠感染隐匿性HBV会影响素的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙肝人，TH1细胞活素表达显著并与肝免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢性丙型肝炎（CHC）中纤维化进展以及对抗毒治疗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接α素包括派罗欣治疗时存在肝功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的人是肝炎的高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在肝感染者中，重叠感染隐匿性HBV会影响干扰素的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性肝人，TH1细胞活素表达显著并与肝免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢性肝炎（CHC）中进展以及对抗毒治疗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬的慢性肝（CHC）者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的患型肝炎的高危。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

肝感染者中，重叠感染隐匿HBV会影响干扰素的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，肝，TH1细胞活素表达显著并与肝免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿型肝炎（CHC）中纤维化进展以及对抗毒治疗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的肝（CHC）患者接受α干扰素包括派罗欣治疗时存肝功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的人是患丙型肝炎的高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙肝感染者中，重叠感染隐匿性HBV会影响干扰的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙肝人，TH1细胞活表达显著并与肝免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛抵抗和糖尿是慢性丙型肝炎（CHC）中纤维化进展以及对抗毒治疗无应答的危险。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

并肝硬化的慢性丙肝（CHC）患者接受α干扰包括派罗欣治疗时存在肝功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品人是患丙型炎高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙感染者中，重叠感染隐匿性HBV会影响干扰素。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙人，TH1细胞活素表达显著并疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢性丙型炎（CHC）中纤维化进展以及对抗毒治无应答危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化慢性丙（CHC）患者接受α干扰素包括派罗欣治时存在功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的人是患丙型炎的高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙者中，重叠隐匿性HBV会影响干扰素的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙人，TH1细胞活素表达显著并与免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和是慢性丙型炎（CHC）中纤维化进展以及对抗毒治疗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性丙（CHC）患者接受α干扰素包括派罗欣治疗时存在功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

注射品的人是患丙型肝炎的高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙肝感染者中，重叠感染隐匿性HBV会影响干扰素的效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙肝人，TH1细胞活素表达显著并与肝免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢性丙型肝炎（CHC）中纤维化进展以及对抗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干扰素包括派罗欣时存在肝功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的人是丙的高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙感染中，重叠感染隐匿性HBV会影响干扰素的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙人，TH1细胞活素表达显著并与免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢性丙（CHC）中纤维化进展以及对抗毒治疗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性丙（CHC）接受α干扰素包括派罗欣治疗时存在功能失代偿和死亡风险。

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的人是丙的高危人。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在丙感染中，重叠感染隐匿性HBV会影响干扰素的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙人，TH1细胞活素表达显著并与免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢性丙（CHC）中纤维化进展以及对抗毒治疗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性丙（CHC）接受α干扰素包括派罗欣治疗时存在功能失代偿和死亡风险。